Nasser-Ghodsi N, et al. - In view of the common occurrence of gastrointestinal (GI) malignancies after liver transplantation, researchers herein investigated the risk and timing of the more common GI malignancies, colorectal and pancreatic cancer, that may aid in optimization in potential posttransplant screening practices. From the United Network for Organ Sharing database, they analyzed data of all adult liver-transplant recipients from 1997 to 2017 and made a comparison with cancer incidence from general population data utilizing Surveillance, Epidemiology, and End Results data. They identified 866 de novo GI malignancies; 405 of these were colorectal and 216 were pancreatic malignancies. Recipients with primary sclerosing cholangitis (PSC), recipients over the age of 50 with non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)/cholangiocarcinoma (CCA), and females > 50 years with alcohol-associated liver disease and HCC/CCA had the highest cumulative incidence for colorectal cancer, with risk rising above the general population within 5 years of transplant. The highest cumulative incidence of pancreatic cancer was observed among patients with PSC and HCC/CCA or NASH and HCC/CCA, which also rose within 5 years following transplant, with those patients > 50 years old conferring the highest risk.